ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Atezolizumab is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 5:03 AM UTC“Added to platinum and etoposide, then as maintenance”
  • The role rule says the same.
  • So Atezolizumab's page lists this study under “Testing it”.
5 links0 made here, not in the record9 judgments2 judges (the rules as one: Rule based)19 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05058651Evaluating the Addition ofthe Immunotherapy DrugAtezolizumab to StandardChemotherapy Treatment forAdvanced or MetastaticNeuroendocrine CarcinomasThat Originate Outside theNational Cancer Institute (NCIPhase 2/Phase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 30 · ClinicalTrials.gov record · Version of 2026-09-30Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Oct 7 · ClinicalTrials.gov record · Version of 2026-10-07Oct 8 · ClinicalTrials.gov record · Version of 2026-10-08Oct 13 · ClinicalTrials.gov record · Version of 2026-10-13Oct 14 · ClinicalTrials.gov record · Version of 2026-10-14Oct 15 · ClinicalTrials.gov record · Version of 2026-10-15Oct 16 · ClinicalTrials.gov record · Version of 2026-10-16Oct 20 · ClinicalTrials.gov record · Version of 2026-10-20Oct 22 · ClinicalTrials.gov record · Version of 2026-10-22Oct 23 · ClinicalTrials.gov record · Version of 2026-10-23Oct 27 · ClinicalTrials.gov record · Version of 2026-10-27Oct 29 · ClinicalTrials.gov record · Version of 2026-10-29Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Nov 4 · ClinicalTrials.gov record · Version of 2026-11-04Nov 6 · ClinicalTrials.gov record · Version of 2026-11-06Nov 12 · ClinicalTrials.gov record · Version of 2026-11-12Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Nov 20 · ClinicalTrials.gov record · Version of 2026-11-20Version of 2026-11-20CONDITIONSCarcinoma, NeuroendocrineNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSAtezolizumabIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEtoposideIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
19 versions of the record seen on ClinicalTrials.gov, Sep 30–Nov 20 · changes seen, not judgments
Nov 3AtezolizumabClaude Opus 5.5TestedCurrent
Nov 3CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 3CisplatinClaude Opus 5.5BackgroundCurrent
Nov 3EtoposideClaude Opus 5.5BackgroundCurrent
Nov 18AtezolizumabRule based · role ruleTestedAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18EtoposideRule based · role ruleBackgroundAgrees
As of nowCarcinoma, NeuroendocrineRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.